Cyclerion Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thanks very much, everybody. Happy to be here moderating a fireside chat with Jonathan Violin, President and CEO of Korsana Biosciences. Some folks listening may be new to the story, so I was kind of thinking maybe, Jonathan, you can give sort of a three-minute overview and background of the company and KRSA-028, and then we can do Q&A. How does that sound? Perfect.
Thank you, Paul. Okay. Thank you.
Thank you, Paul and the Stifel team for having us here. Really a pleasure to be at the conference, and to have you covering the story. Korsana's a relatively new company. We just came public in September via reverse merger, very well capitalized. We reported $456 million on the balance sheet, as of the end of September. And we are here to try to make a dent in Alzheimer's disease, obviously one of the biggest unmet needs in medicine today. And we think that this indication is at an inflection point. We have two disease-modifying therapies on the market, but while they slow cognitive decline, they are far from optimal.
Then we have in trontinemab from Roche, a true breakthrough, a next-generation medication that both clears amyloid plaques much faster and is much safer in terms of amyloid-related imaging abnormalities, ARIA, microedema, microhemorrhage, which has been a series of adverse events that has plagued this category. Trontinemab is better in both of those. Faster plaque clearance, far lower rates of ARIA, but still is not the end of the road. It is given intravenously, it has a very high rate of infusion-related reactions such that all patients have been pretreated with corticosteroids in phase III, and it has a moderate rate of anemia. So while we think Roche has done a fantastic job, we think it is really a true breakthrough product, there is more to do yet at this target for these patients.
So when we set out at Korsana to make a new molecule in this class, we really thought carefully about what does it take to maximize the benefit we can give patients in clearing amyloid? We think, at least based on our preclinical data, that is what we have achieved. We are approaching the clinic and expecting our first clinical data next year, healthy volunteer data mid-year next year, and then our interim proof of concept data in patients by the end of next year or the first quarter of 2028. So a lot of excitement ahead for us.
Yeah. Okay, great. Well, maybe we can sort of break down the thought process behind KRSA-028 and the different sort of points of potential differentiation. But starting with the mechanism of action, maybe talk about the thought process for targeting pyroglutamate A-beta and why you thought this was the right mechanism.
There is a really nice correlation if you look at all the phase III studies, so the biggest, best-run studies for amyloid-targeted antibodies. If you look at the first-generation unshuttled antibodies, so require very high doses to get enough drug in the brain, so excluding trontinemab, there is a striking correlation between plaque clearance as measured by PET tracers, which is extremely sensitive, and slowing of cognitive decline measured by CDR-SB. If you look at that set of data points, there are some molecules that failed, and there are explanations for why they failed. But the very best plaque clearance, and at least numerically, the best slowing of cognitive decline is donanemab, which targets pyroglutamate-modified forms of amyloid. That pyroglutamate post-translational modification makes amyloid more sticky, helps promote plaque formation.
You can think of donanemab as more plaque-selective as opposed to various other forms of amyloid. When we look at the donanemab data, in addition, remternetug, which is a next-generation molecule Lilly is advancing, also selective for pyroglutamate forms of amyloid, that target, that form of the target clearly delivers the fastest and deepest plaque reduction. If you're starting from scratch thinking, "How do I make a molecule that's hard to beat?" drugs like lecanemab that are more broad-spectrum amyloid binders clearly work. The data suggests that pyroglutamate is the place to be for a starting point.
On the safety side, I mean, I think the biggest revelation within the trontinemab data is the ability to decouple plaque lowering from ARIA. What do we understand about this biologically in terms of why this is happening, and how confident can we be that this is an extrapolatable finding to other shuttle programs?
Yeah, that was the, I think, biggest surprise in the trontinemab program. It used to be we thought that ARIA was inextricable from clearing plaque, and that if the antibody bound plaque and promoted its clearance, that you would cause ARIA. The reason that happens, though, is because to get enough unshuttled antibody into the brain, you have to give very high doses, leading to very high peripheral exposures, and you end up with a crowding of antibodies with all the immune function that antibodies bring to bear in the large vessels of the brain, where it can accumulate and just damage the local blood vessels. That's why when you have these plaques driving peripheral concentrations very high, can result in these findings. With trontinemab, with this shuttling technology, we can get much higher brain levels with much lower doses, lower peripheral exposure.
You can see that in studies that Roche and others have done, that rather than requiring huge doses to crowd in through the large vessels of the brain, by binding the transferrin receptor and enabling shuttling across the blood-brain barrier, these lower doses, lower peripheral concentrations get more evenly throughout the brain. That's how we can selectively attack the plaques that are causing amyloid, that are causing Alzheimer's disease, with a much, much lower rate of ARIA.
Yep. Okay, great. I think the other question with transferrin binders in general is anemia risk. I probably wouldn't rank that as important as ARIA, but how comfortable are you that you'll be able to have lower rates of anemia than some of the other competing programs out there with KRSA-028?
Yeah. Anemia is certainly one of the factors that has been a problem for the entire field of transferrin receptor shuttling. Today, we're sitting on two or three decades worth of lessons in how can you engage transferrin receptor, which is part of iron homeostasis, right, a core biological process. How can you do that without causing harm? We've learned along the way you need to target the transferrin receptor with the right affinity, with the right epitope, so you still allow transferrin to bind and do its job. The remaining issue that we see with trontinemab is an acute reticulocyte depletion, which we reasoned could have been caused by CDC or ADCC, two of the effector functions that a normal wild type antibody brings to bear. When we designed KRSA-028, we wanted to preserve the beneficial effects of phagocytosis. That's how plaques are cleared.
But we wanted to try to spare reticulocytes with knocking down CDC and ADCC, and our preclinical data suggests that's what we've done. That's just one piece of how we think we can make a best-in-class molecule. We're aiming to be subQ, better local tolerability. Hopefully, we can reduce anemia. Then the benefits of the transferrin receptor are dramatically lower, potentially even placebo-like rates of ARIA.
Maybe talk a little bit about the different work you've done on the preclinical side, and walk us through Korsana's thought process in taking the preclinical data and being able to make a confident prediction around human dose range, frequency of subQ, things like that. I guess the sort of bottom line, what is your level of confidence that all this preclinical work should reliably translate?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
